StemCells, Inc. is applying its scientific and industry leadership in stem cell biology to discover, develop and commercialize breakthrough therapeutics and enabling tools and technologies for research and drug discovery.
Credited with an impressive record of discoveries and firsts, the StemCells, Inc. team has a distinguished heritage of scientific achievement in stem cell biology. An unwavering commitment to rigorous science characterizes our culture, guiding our scientific and clinical integrity, as well as our business principles.
StemCells, Inc. is the first and only company to complete a US clinical trial using human neural stem cells, tackling central nervous system (CNS) disorders with our HuCNS-SC® product candidate. Our liver program is also among the first of its kind, targeting liver disease with our proprietary hLEC™ human liver engrafting cells.
Today, our tools and technologies are transforming stem cell-based research, drug discovery and development. On the horizon, is the great promise of cell-based therapeutics to treat, and possibly cure, a broad range of human diseases. Follow our progress as we work to make this vision a reality.
Listed on the NASDAQ Market since 1992, we are committed to balancing our standards of scientific rigor and clinical integrity with our corporate imperatives of value creation and long-term business sustainability.
StemCells, Inc. scientists are internationally renowned, as is our reputation for pioneering research in stem cell biology and innovation in stem cell technology. With operations in the United States and the United Kingdom, our capabilities and facilities span the globe.
“…it is one thing to say that stem cells have the potential to do something; it is quite another to figure out how to reveal that potential and control it.”
